The Efficacy and Safety of Inetetamab and Pyrotinib in Combination withVinorelbine for Second-line Therapy and Beyond in HER2-positiveMetastatic Breast Cancer: A Single-institution Clinical Experience

Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥ 2^nd-line treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2^nd-line treatment.